Sonnet BioTherapeutics Announces Notice of Allowance for Second Patent on Variant Interleukin-18 Binding Protein for Enhanced Cancer Therapeutics

Quiver QuantitativeMar 19 09:00 ET

Sonnet BioTherapeutics Receives Notice Of Allowance For U.S. Patent Covering Composition Of Matter Of Specific Amino Acid Substitutions Of Its IL-18 Binding Protein Resistant Variant Protein

BenzingaMar 19 08:51 ET

Express News | Sonnet Biotherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein

ReutersMar 19 08:50 ET

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for '25" Conference

Quiver QuantitativeMar 11 08:50 ET

Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

AccesswireMar 11 08:45 ET

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

GlobeNewswireFeb 26 09:00 ET